New Application of an Old Drug: Anti-Diabetic Properties of Phloroglucinol.

Autor: Drygalski K; Department of Hypertension and Diabetology, Medical University of Gdansk, 80-214 Gdansk, Poland., Maciejczyk M; Department of Hygiene, Epidemiology and Ergonomics, Medical University of Bialystok, 15-089 Bialystok, Poland., Miksza U; Clinical Research Support Centre, Medical University of Bialystok, 15-089 Bialystok, Poland., Ustymowicz A; Department of Radiology, Medical University of Bialystok, 15-089 Bialystok, Poland., Godzień J; Clinical Research Centre, Medical University of Bialystok, 15-089 Bialystok, Poland., Buczyńska A; Clinical Research Centre, Medical University of Bialystok, 15-089 Bialystok, Poland., Chomentowski A; Department of Biophysics, Medical University of Bialystok, 15-089 Bialystok, Poland., Walczak I; Department of Biochemistry, Medical University of Gdansk, 80-214 Gdansk, Poland., Pietrowska K; Clinical Research Centre, Medical University of Bialystok, 15-089 Bialystok, Poland., Siemińska J; Clinical Research Centre, Medical University of Bialystok, 15-089 Bialystok, Poland., Pawlukianiec C; Students Scientific Club 'Biochemistry of Civilization Diseases', Department of Hygiene, Epidemiology and Ergonomics, Medical University of Bialystok, 15-089 Bialystok, Poland., Czajkowski P; Clinical Research Support Centre, Medical University of Bialystok, 15-089 Bialystok, Poland., Fiedorczuk J; Clinical Research Support Centre, Medical University of Bialystok, 15-089 Bialystok, Poland., Moroz M; Clinical Research Support Centre, Medical University of Bialystok, 15-089 Bialystok, Poland., Modzelewska B; Department of Biophysics, Medical University of Bialystok, 15-089 Bialystok, Poland., Zalewska A; Experimental Dentistry Laboratory, Medical University of Bialystok, 15-089 Bialystok, Poland., Kutryb-Zając B; Department of Biochemistry, Medical University of Gdansk, 80-214 Gdansk, Poland., Kleszczewski T; Department of Biophysics, Medical University of Bialystok, 15-089 Bialystok, Poland., Ciborowski M; Clinical Research Centre, Medical University of Bialystok, 15-089 Bialystok, Poland., Hady HR; Clinical Department of General and Endocrine Surgery, Medical University of Bialystok, 15-089 Bialystok, Poland., Foretz M; Institut Cochin, Université Paris Cité, CNRS, INSERM, F-75014 Paris, France., Adamska-Patruno E; Clinical Research Support Centre, Medical University of Bialystok, 15-089 Bialystok, Poland.
Jazyk: angličtina
Zdroj: International journal of molecular sciences [Int J Mol Sci] 2024 Sep 24; Vol. 25 (19). Date of Electronic Publication: 2024 Sep 24.
DOI: 10.3390/ijms251910291
Abstrakt: Phloroglucinol (PHG), an analgesic and spasmolytic drug, shows promise in preventing high-fat-diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD) and insulin resistance. In Wistar rats, 10 weeks of PHG treatment did not prevent HFD-induced weight gain but significantly mitigated fasting hyperglycemia, impaired insulin responses, and liver steatosis. This protective effect was not linked to hepatic lipogenesis or AMP-activated protein kinase (AMPK) activation. Instead, PHG improved mitochondrial function by reducing oxidative stress, enhancing ATP production, and increasing anti-oxidant enzyme activity. PHG also relaxed gastric smooth muscles via potassium channel activation and nitric oxide (NO) signaling, potentially delaying gastric emptying. A pilot intervention in pre-diabetic men confirmed PHG's efficacy in improving postprandial glycemic control and altering lipid metabolism. These findings suggest PHG as a potential therapeutic for NAFLD and insulin resistance, acting through mechanisms involving mitochondrial protection, anti-oxidant activity, and gastric motility modulation. Further clinical evaluation is warranted to explore PHG's full therapeutic potential.
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje